JP2023500923A - 大腸癌検出方法 - Google Patents
大腸癌検出方法 Download PDFInfo
- Publication number
- JP2023500923A JP2023500923A JP2022526188A JP2022526188A JP2023500923A JP 2023500923 A JP2023500923 A JP 2023500923A JP 2022526188 A JP2022526188 A JP 2022526188A JP 2022526188 A JP2022526188 A JP 2022526188A JP 2023500923 A JP2023500923 A JP 2023500923A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- methylated
- adhfe1
- methylation
- sdc2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 54
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 33
- 238000001514 detection method Methods 0.000 title claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 50
- 238000000034 method Methods 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 22
- 238000003745 diagnosis Methods 0.000 claims abstract description 15
- 230000011987 methylation Effects 0.000 claims description 70
- 238000007069 methylation reaction Methods 0.000 claims description 70
- 101150031702 adhfe1 gene Proteins 0.000 claims description 54
- 239000000523 sample Substances 0.000 claims description 40
- 101150118392 sdc-2 gene Proteins 0.000 claims description 29
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims description 17
- 102100034132 Hydroxyacid-oxoacid transhydrogenase, mitochondrial Human genes 0.000 claims description 16
- 102000003711 Syndecan-2 Human genes 0.000 claims description 16
- 108090000054 Syndecan-2 Proteins 0.000 claims description 16
- 238000012163 sequencing technique Methods 0.000 claims description 14
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical group OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 12
- 230000000295 complement effect Effects 0.000 claims description 12
- 238000007855 methylation-specific PCR Methods 0.000 claims description 12
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 10
- 238000003753 real-time PCR Methods 0.000 claims description 10
- 229940104302 cytosine Drugs 0.000 claims description 9
- 230000009870 specific binding Effects 0.000 claims description 8
- 102000023732 binding proteins Human genes 0.000 claims description 6
- 108091008324 binding proteins Proteins 0.000 claims description 6
- 238000007841 sequencing by ligation Methods 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 101001017404 Homo sapiens Hydroxyacid-oxoacid transhydrogenase, mitochondrial Proteins 0.000 claims description 5
- 229940035893 uracil Drugs 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 claims description 3
- 229940079826 hydrogen sulfite Drugs 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 101000692109 Homo sapiens Syndecan-2 Proteins 0.000 claims 3
- 102100026087 Syndecan-2 Human genes 0.000 claims 3
- 239000000439 tumor marker Substances 0.000 abstract description 9
- 238000010586 diagram Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 54
- 239000013615 primer Substances 0.000 description 43
- 150000007523 nucleic acids Chemical class 0.000 description 37
- 108020004707 nucleic acids Proteins 0.000 description 33
- 102000039446 nucleic acids Human genes 0.000 description 33
- 230000003321 amplification Effects 0.000 description 16
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 16
- 238000003199 nucleic acid amplification method Methods 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 14
- 108091029523 CpG island Proteins 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 230000010261 cell growth Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000005856 abnormality Effects 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 108091029430 CpG site Proteins 0.000 description 5
- 101000771163 Homo sapiens Collagen alpha-1(II) chain Proteins 0.000 description 5
- 210000004953 colonic tissue Anatomy 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 239000003155 DNA primer Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000007481 next generation sequencing Methods 0.000 description 4
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 238000001369 bisulfite sequencing Methods 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- VUIKXKJIWVOSMF-GHTOIXBYSA-N d(CG)12 Chemical group O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 VUIKXKJIWVOSMF-GHTOIXBYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 101150117538 Set2 gene Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000002052 colonoscopy Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002987 primer (paints) Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012175 pyrosequencing Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- 101150082216 COL2A1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100029136 Collagen alpha-1(II) chain Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 102100029768 Histone-lysine N-methyltransferase SETD1A Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000865038 Homo sapiens Histone-lysine N-methyltransferase SETD1A Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000006607 hypermethylation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000000968 medical method and process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
Description
Claims (21)
- 次の段階を含む、大腸癌診断のための情報を提供する方法:
(a)メチル化されたSDC2(Syndecan 2)遺伝子及びADHFE1(Alcohol Dehydrogenase Iron Containing 1)遺伝子、及び非メチル化されたSDC2遺伝子及びADHFE1遺伝子を互いに異なるように変形させる一つ以上の試薬でサンプルを処理する段階;及び
(b)メチル化されたSDC2遺伝子及びADHFE1遺伝子を特異的に増幅するプライマーを処理する段階。 - 前記試薬は、バイサルファイト(bisulfite)、ヒドロゲンサルファイト(hydrogen sulfite)、ジサルファイト(disulfite)又はこれらの組合せであることを特徴とする、請求項1に記載の方法。
- 前記試薬処理によって少なくとも一つのシトシン塩基が、ウラシル又はシトシン以外の塩基に変換されることを特徴とする、請求項1に記載の方法。
- 前記メチル化されたADHFE1遺伝子を特異的に増幅するプライマーは、配列番号1又は4の配列を含むことを特徴とする、請求項1に記載の方法。
- 前記メチル化されたADHFE1遺伝子を特異的に増幅するプライマーは、配列番号2又は5の配列をさらに含むことを特徴とする、請求項4に記載の方法。
- 前記メチル化されたSDC2遺伝子を特異的に増幅するプライマーは、配列番号10又は11の配列を含むことを特徴とする、請求項1に記載の方法。
- (c)前記(b)段階でプライマーによって特異的に増幅されたメチル化SDC2遺伝子及びメチル化ADHFE1遺伝子にそれぞれ相補的にハイブリダイズ可能なプローブを処理する段階をさらに含むことを特徴とする、請求項1に記載の方法。
- 前記増幅されたメチル化ADHFE1遺伝子に相補的にハイブリダイズ可能なプローブは、配列番号3又は6の配列を含むことを特徴とする、請求項7に記載の方法。
- 前記増幅されたメチル化SDC2遺伝子に相補的にハイブリダイズ可能なプローブは、配列番号12の配列を含むことを特徴とする、請求項7に記載の方法。
- 前記メチル化検出は、PCR、メチル化特異PCR(methylation specific PCR)、リアルタイムメチル化特異PCR(real time methylation specific PCR)、メチル化DNA特異的結合タンパク質を用いたPCR、メチル化DNA特異的結合抗体を用いたPCR、定量PCR、遺伝子チップ、シーケンシング、シーケンシングバイシンセシス(Sequencing by synthesis)及びシーケンシングバイライゲーション(Sequencing by ligation)からなる群から選ばれる方法によって行われることを特徴とする、請求項1に記載の方法。
- 前記プローブに結合して蛍光を示す物質を検出することによって、メチル化を検出することを特徴とする、請求項7に記載の方法。
- メチル化されたSDC2(Syndecan 2)遺伝子及びADHFE1(Alcohol Dehydrogenase Iron Containing 1)遺伝子、及び非メチル化されたSDC2遺伝子及びADHFE1遺伝子を互いに異なるように変形させる一つ以上の試薬;及び
前記メチル化されたSDC2遺伝子及びADHFE1遺伝子を特異的に増幅するプライマーを含む大腸癌診断用組成物。 - 前記試薬は、バイサルファイト(bisulfite)、ヒドロゲンサルファイト(hydrogen sulfite)、ジサルファイト(disulfite)又はそれらの組合せであることを特徴とする、請求項12に記載の組成物。
- 前記試薬処理によって少なくとも一つのシトシン塩基が、ウラシル又はシトシン以外の塩基に変換されることを特徴とする、請求項12に記載の組成物。
- 前記メチル化されたADHFE1遺伝子を特異的に増幅するプライマーは、配列番号1又は4の配列を含むことを特徴とする、請求項12に記載の組成物。
- 前記メチル化されたADHFE1遺伝子を特異的に増幅するプライマーは、配列番号2又は5の配列をさらに含むことを特徴とする、請求項12に記載の組成物。
- 前記メチル化されたSDC2遺伝子を特異的に増幅するプライマーは、配列番号10又は11の配列を含むことを特徴とする、請求項12に記載の組成物。
- 前記プライマーによって特異的に増幅されたメチル化SDC2遺伝子とADHFE1遺伝子にそれぞれ相補的にハイブリダイズ可能なプローブをさらに含む、請求項12に記載の組成物。
- 前記増幅されたメチル化ADHFE1遺伝子に相補的にハイブリダイズ可能なプローブは、配列番号3又は6の配列を含むことを特徴とする、請求項18に記載の組成物。
- 前記増幅されたメチル化SDC2遺伝子に相補的にハイブリダイズ可能なプローブは、配列番号12の配列を含むことを特徴とする、請求項18に記載の組成物。
- 請求項12~20のいずれか一項に記載の組成物を含む大腸癌診断用キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0141548 | 2019-11-07 | ||
KR1020190141548A KR102261606B1 (ko) | 2019-11-07 | 2019-11-07 | 대장암 검출 방법 |
PCT/KR2020/015360 WO2021091239A1 (ko) | 2019-11-07 | 2020-11-05 | 대장암 검출 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023500923A true JP2023500923A (ja) | 2023-01-11 |
Family
ID=75848907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022526188A Pending JP2023500923A (ja) | 2019-11-07 | 2020-11-05 | 大腸癌検出方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230002830A1 (ja) |
EP (1) | EP4056715A4 (ja) |
JP (1) | JP2023500923A (ja) |
KR (1) | KR102261606B1 (ja) |
CN (1) | CN114667355A (ja) |
WO (1) | WO2021091239A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114507740B (zh) * | 2022-04-19 | 2022-07-29 | 广州滴纳生物科技有限公司 | 用于胃肠癌诊断的生物标志物、核酸产品和试剂盒 |
WO2024045170A1 (zh) * | 2022-09-02 | 2024-03-07 | 深圳华大基因股份有限公司 | 差异性甲基化区域组合、试剂盒和用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013509872A (ja) * | 2009-11-05 | 2013-03-21 | ゲノミクトリー インコーポレーテッド | 腸癌診断のための腸癌特異的メチル化マーカー遺伝子のメチル化検出方法 |
WO2014062218A1 (en) * | 2012-10-16 | 2014-04-24 | University Of Southern California | Colorectal cancer dna methylation markers |
JP2017516504A (ja) * | 2014-06-04 | 2017-06-22 | クエスト ダイアグノスティクス インベストメンツ インコーポレイテッド | 結腸直腸癌のためのメチル化マーカー |
WO2018165366A1 (en) * | 2017-03-08 | 2018-09-13 | President And Fellows Of Harvard College | Methods of amplifying dna to maintain methylation status |
JP2019501651A (ja) * | 2015-12-31 | 2019-01-24 | 広州市康立明生物科技有限責任公司Creative Biosciences (Guangzhou) Co., Ltd. | 腫瘍分子の検出/診断試薬 |
US20190284608A1 (en) * | 2016-10-06 | 2019-09-19 | Genomictree, Inc. | Method for multiplex detection of methylated dna |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008073915A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
WO2013057581A2 (en) * | 2011-10-17 | 2013-04-25 | King Abdullah University Of Science And Technology | Composite biomarkers for non-invasive screening, diagnosis and prognosis of colorectal cancer |
WO2015023146A1 (ko) * | 2013-08-14 | 2015-02-19 | (주)지노믹트리 | 전암병변의 검출방법 |
CA2938451C (en) * | 2014-01-30 | 2023-10-17 | The Regents Of The University Of California | Methylation haplotyping for non-invasive diagnosis (monod) |
RU2630669C1 (ru) * | 2016-07-21 | 2017-09-11 | Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" (ФБУН ГНЦ ВБ "Вектор") | Способ определения метилирования сайтов PuCGPy регуляторных областей генов-онкомаркеров колоректального рака методом GLAD-ПЦР-анализа и набор олигонуклеотидных праймеров и флуоресцентно-меченых зондов для осуществления указанного способа |
WO2018087129A1 (en) * | 2016-11-08 | 2018-05-17 | Region Nordjylland, Aalborg University Hospital | Colorectal cancer methylation markers |
CN108410980B (zh) * | 2018-01-22 | 2022-02-01 | 华大数极生物科技(深圳)有限公司 | 筛选甲基化pcr检测的目标区域的方法、试剂盒及应用 |
-
2019
- 2019-11-07 KR KR1020190141548A patent/KR102261606B1/ko active IP Right Grant
-
2020
- 2020-05-22 US US17/765,515 patent/US20230002830A1/en active Pending
- 2020-11-05 WO PCT/KR2020/015360 patent/WO2021091239A1/ko unknown
- 2020-11-05 JP JP2022526188A patent/JP2023500923A/ja active Pending
- 2020-11-05 EP EP20885850.6A patent/EP4056715A4/en active Pending
- 2020-11-05 CN CN202080077651.4A patent/CN114667355A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013509872A (ja) * | 2009-11-05 | 2013-03-21 | ゲノミクトリー インコーポレーテッド | 腸癌診断のための腸癌特異的メチル化マーカー遺伝子のメチル化検出方法 |
WO2014062218A1 (en) * | 2012-10-16 | 2014-04-24 | University Of Southern California | Colorectal cancer dna methylation markers |
JP2017516504A (ja) * | 2014-06-04 | 2017-06-22 | クエスト ダイアグノスティクス インベストメンツ インコーポレイテッド | 結腸直腸癌のためのメチル化マーカー |
JP2019501651A (ja) * | 2015-12-31 | 2019-01-24 | 広州市康立明生物科技有限責任公司Creative Biosciences (Guangzhou) Co., Ltd. | 腫瘍分子の検出/診断試薬 |
US20190284608A1 (en) * | 2016-10-06 | 2019-09-19 | Genomictree, Inc. | Method for multiplex detection of methylated dna |
WO2018165366A1 (en) * | 2017-03-08 | 2018-09-13 | President And Fellows Of Harvard College | Methods of amplifying dna to maintain methylation status |
Non-Patent Citations (4)
Title |
---|
BIOLOGY AND MEDICINE, vol. 8, no. 7, JPN7023002020, 2016, pages 1000342, ISSN: 0005072013 * |
BMC CANCER, vol. 13, JPN7023002019, 2013, pages 142, ISSN: 0005072016 * |
EPIGENETICS, vol. Vol.8-9, JPN6023021363, 2013, pages 921 - 934, ISSN: 0005072014 * |
JOURNAL OF CANCER, vol. 10, no. 21, JPN7023002021, 28 August 2019 (2019-08-28), pages 5264 - 5271, ISSN: 0005072015 * |
Also Published As
Publication number | Publication date |
---|---|
US20230002830A1 (en) | 2023-01-05 |
WO2021091239A1 (ko) | 2021-05-14 |
EP4056715A4 (en) | 2023-12-27 |
EP4056715A1 (en) | 2022-09-14 |
CN114667355A (zh) | 2022-06-24 |
KR20210055281A (ko) | 2021-05-17 |
KR102261606B1 (ko) | 2021-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11473148B2 (en) | Methods of diagnosing bladder cancer | |
JP5394409B2 (ja) | 肺癌特異的メチル化マーカー遺伝子を利用した肺癌検出方法 | |
US11186866B2 (en) | Method for multiplex detection of methylated DNA | |
EP2395114B1 (en) | Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene | |
EP2918679B1 (en) | Method for detecting gastric polyp and gastric cancer using marker gene of gastric polyp and gastric cancer-specific methylation | |
KR102223014B1 (ko) | 전암병변의 검출방법 | |
KR101255769B1 (ko) | 장암 진단을 위한 장암 특이적 메틸화 마커 gpm6a 유전자의 메틸화 검출방법 | |
US9670551B2 (en) | Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene | |
JP2023500923A (ja) | 大腸癌検出方法 | |
US9670552B2 (en) | Diagnosis kit and chip for bladder cancer using bladder cancer specific methylation marker gene | |
JP7447155B2 (ja) | Sdc2遺伝子のメチル化検出方法 | |
WO2023229393A1 (ko) | 폐암 검출 방법 | |
KR101200552B1 (ko) | 방광암 특이적 메틸화 마커 유전자를 이용한 방광암 진단용 키트 및 칩 | |
KR101200537B1 (ko) | 방광암 특이적 메틸화 마커 유전자를 이용한 방광암 진단용 키트 및 칩 | |
WO2024075828A1 (ja) | アルツハイマー病を発症する可能性を判定するためのデータ収集方法及びキット | |
WO2021107081A1 (ja) | 上部尿路上皮癌の判定方法 | |
JP2015177745A (ja) | 肺癌の検査方法 | |
CN117721208A (zh) | 血液肿瘤广谱甲基化标志物npbwr1多重扩增体系及试剂盒 | |
CN116555422A (zh) | 肺癌甲基化标志物、检测试剂盒及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220624 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230519 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230530 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231130 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240220 |